Mr. Joyce has 25 years of public company CEO and board leadership experience. At Sigyn Therapeutics, he oversees the advancement of CardioDialysis^TM and has led the design of innovative device candidates to enhance cancer therapy delivery. These include ImmunePrep^TM to optimize the delivery of immunotherapeutic antibodies; ChemoPrep^TM to improve the delivery of chemotherapy; and ChemoPure^TM to reduce chemotherapy toxicity.

Previously, Mr. Joyce was the founder of Aethlon Medical, which he navigated from start-up to Nasdaq-traded company with a peak market value of ~$200 million during his tenure. At Aethlon, he oversaw the development of the Hemopurifier® from concept to becoming the first therapy to receive two FDA “Breakthrough Device” designations and the first medical device cleared by FDA to treat a pandemic virus. TIME magazine named the Hemopurifier® a “Top 25 Invention” and one of the “11 Most Remarkable Advances in Healthcare.”

Mr. Joyce has a diverse range of medical device industry experience:

• With support from Senator Joe Lieberman, he lobbied Capitol Hill and testified before Congress to expand the U.S. Government’s definition of pandemic treatment countermeasure to be inclusive of medical devices. This allowed for the Hemopurifier® to be FDA cleared under Emergency-Use Authorization to treat Ebola virus and subsequently permitted blood purification therapies to become the first four therapies cleared by FDA to treat COVID-19.
• He participated in a 5-year Department of Defense (DOD) program with the Defense Advanced Research Projects Agency (DARPA) to develop blood purification therapies to treat sepsis in wounded warfighters.
• He participated in an FDA expedited-access pathway (EAP) pilot program with the Center for Devices and Radiological Health (CDRH) that preceded the establishment of FDA’s Breakthrough Device program.
• He has originated medical device-related research programs with leading government and non-government research organizations, including the U.S. Centers for Disease Control and Prevention (CDC), the Battelle Memorial Research Institute, the National Cancer Institute (NCI), the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the National Center for Biodefense, the National Institute of Virology (a World Health Organization Research Lab), the Pasteur Institute, DaVita Clinical Research, MD Anderson Cancer Center, Massachusetts General Hospital, University of Pittsburgh Medical Center, Institute of Virology at Philipps University Marburg, and the City of Hope Cancer Research Institute.

Mr. Joyce was also the founder of Exosome Sciences, Inc. (ESI), a Company focused on the discovery of exosomal biomarkers. Inspired by the death of a former teammate, Mr. Joyce established a collaboration with the Boston University CTE Center to evaluate circulating exosomes with tau protein cargos (exosomal tau) as a basis for a non-invasive blood test to diagnose and monitor chronic traumatic encephalopathy (CTE). The Company participated in the first NIH funded study of CTE, which revealed exosomal tau levels to be approximately 9x higher in former NFL players as compared to same age group control subjects. The results of the study were published in the Journal Alzheimer's Disease.

Upon graduating from the University of Maryland, Mr. Joyce was first employed as a member of the Denver Broncos Football Club of the National Football League.

Mr. Roberts is an inventor of life-saving therapeutic technologies, which includes a Percutaneous Adult Extracorporeal Membrane Oxygenation (ECMO) system that was licensed and subsequently sold to C.R. Bard. Mr. Roberts is also an inventor of the IMPACT System, which received CE Mark clearance in the European Union and was subsequently registered in 32 countries and deployed to treat cytokine storm associated conditions, including sepsis, acute respiratory distress syndrome (ARDS), acute liver failure, severe pneumonia, and H5N1 bird flu virus infection. The IMPACT system was comprised of multiple cartridges and designed to reduce the presence of inflammatory cytokines from human blood plasma. As a Clinical Perfusionist, Craig has conducted more than 4,000 extracorporeal procedures, including adult and pediatric cardiopulmonary bypass, cardiac assist devices, ECMO (artificial lung), vascular access catheter systems, and continuous renal replacement therapy.

Jim Dorst has more than 30 years of senior management experience in finance, operations, planning and business transactions at both private and public companies. He was most recently Director of Corporate Development at SYNNEX/Concentrix, where he was primarily responsible for mergers and acquisitions. Mr. Dorst was previously Chief Operating Officer (“COO”) and Chief Financial Officer (“CFO”) at SpectraScience, Inc.; CFO of Aethlon Medical, Inc. and Vice President of Finance and Operations for Verdisoft Corporation. In addition, he previously served as Senior Vice President of Finance and Administration at SeeCommerce; CFO and COO of Omnis Technology Corp; and CFO and Senior Vice President of Information Technology at Savoir Technology Group, Inc. Mr. Dorst practiced as a Certified Public Accountant with Coopers & Lybrand (now PricewaterhouseCoopers LLP); and holds a Master of Science degree in Accounting and a Bachelor of Science degree in Finance from the University of Oregon.